Sulfasalazine and DOX (Doxorubicin) not only activate ferroptosis in breast cancer cells by inhibiting xCT and GPX4 but also regulate ferroptosis by activating iron metabolism by up‐regulating DMT1, transferrin, and transferrin receptors [18, 19]. Here, SLC11A2 is linked to breast carcinoma.